MP29-12 CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH RELUGOLIX: A SINGLE CENTER EXPERIENCE

CONCLUSIONS: The majority of patients who were prescribed relugolix had at least 1 cardiac comorbidity, and the subsequent rate of major adverse cardiac events was similar to the HERO registrational trial (4.8% vs 3.6%). Our fi ndings illustrate a real-world experience of patients initiating therapy with relugolix, comorbidities present at initia- tion, providers managing the drug, and cardiovascular and survival outcomes following its use